ALDX
Price
$2.02
Change
-$0.03 (-1.46%)
Updated
Jun 23, 04:59 PM (EDT)
Capitalization
121.85M
38 days until earnings call
Intraday BUY SELL Signals
CLLS
Price
$2.94
Change
+$0.12 (+4.26%)
Updated
Jun 23, 04:14 PM (EDT)
Capitalization
282.55M
37 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ALDX vs CLLS

ALDX vs CLLS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALDX vs. CLLS commentary
Jun 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALDX is a Hold and CLLS is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 24, 2026
Stock price -- (ALDX: $2.05 vs. CLLS: $2.81)
Brand notoriety: ALDX and CLLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALDX: 158% vs. CLLS: 58%
Market capitalization -- ALDX: $121.85M vs. CLLS: $308.15M
ALDX [@Biotechnology] is valued at $121.85M. CLLS’s [@Biotechnology] market capitalization is $308.15M. The market cap for tickers in the [@Biotechnology] industry ranges from $118.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALDX’s FA Score shows that 1 FA rating(s) are green whileCLLS’s FA Score has 0 green FA rating(s).

  • ALDX’s FA Score: 1 green, 4 red.
  • CLLS’s FA Score: 0 green, 5 red.
According to our system of comparison, both ALDX and CLLS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALDX’s TA Score shows that 5 TA indicator(s) are bullish while CLLS’s TA Score has 4 bullish TA indicator(s).

  • ALDX’s TA Score: 5 bullish, 4 bearish.
  • CLLS’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ALDX is a better buy in the short-term than CLLS.

Price Growth

ALDX (@Biotechnology) experienced а +16.48% price change this week, while CLLS (@Biotechnology) price change was -9.65% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.89%. For the same industry, the average monthly price growth was +2.09%, and the average quarterly price growth was +1952.22%.

Reported Earning Dates

ALDX is expected to report earnings on Jul 31, 2026.

CLLS is expected to report earnings on Jul 30, 2026.

Industries' Descriptions

@Biotechnology (+5.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLLS($283M) has a higher market cap than ALDX($122M). CLLS YTD gains are higher at: -41.944 vs. ALDX (-60.425). ALDX has higher annual earnings (EBITDA): -25.22M vs. CLLS (-39.82M). CLLS has more cash in the bank: 186M vs. ALDX (65M). ALDX has less debt than CLLS: ALDX (15.5M) vs CLLS (86.5M). CLLS has higher revenues than ALDX: CLLS (68.1M) vs ALDX (0).
ALDXCLLSALDX / CLLS
Capitalization122M283M43%
EBITDA-25.22M-39.82M63%
Gain YTD-60.425-41.944144%
P/E RatioN/AN/A-
Revenue068.1M-
Total Cash65M186M35%
Total Debt15.5M86.5M18%
FUNDAMENTALS RATINGS
ALDX vs CLLS: Fundamental Ratings
ALDX
CLLS
OUTLOOK RATING
1..100
386
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
37
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9999
PRICE GROWTH RATING
1..100
5959
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALDX's Valuation (26) in the Biotechnology industry is in the same range as CLLS (37). This means that ALDX’s stock grew similarly to CLLS’s over the last 12 months.

ALDX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLLS (100). This means that ALDX’s stock grew similarly to CLLS’s over the last 12 months.

ALDX's SMR Rating (99) in the Biotechnology industry is in the same range as CLLS (99). This means that ALDX’s stock grew similarly to CLLS’s over the last 12 months.

ALDX's Price Growth Rating (59) in the Biotechnology industry is in the same range as CLLS (59). This means that ALDX’s stock grew similarly to CLLS’s over the last 12 months.

ALDX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CLLS (100). This means that ALDX’s stock grew similarly to CLLS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALDXCLLS
RSI
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
72%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 14 days ago
78%
Declines
ODDS (%)
Bearish Trend 14 days ago
79%
Bearish Trend 2 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
ALDX
Daily Signal:
Gain/Loss:
CLLS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NWAPX40.320.23
+0.57%
Nationwide BNY Mellon Dyn US Eq Inc Egl
OTCJX28.60N/A
N/A
MFS Mid Cap Growth R4
TBHDX6.32N/A
N/A
Tweedy, Browne . Buybacks . Divs+Val Fd
FIQVX44.93N/A
N/A
Fidelity Advisor Convertible Secs Z
JICCX81.99N/A
N/A
JPMorgan US Sustainable Leaders C

CLLS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CLLS has been loosely correlated with SLN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLLS jumps, then SLN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLLS
1D Price
Change %
CLLS100%
-5.71%
SLN - CLLS
43%
Loosely correlated
+8.80%
MDGL - CLLS
40%
Loosely correlated
+1.59%
PMVP - CLLS
38%
Loosely correlated
+0.88%
AXON - CLLS
36%
Loosely correlated
-3.16%
TGTX - CLLS
36%
Loosely correlated
+2.20%
More